We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Detection Method Identifies Protein Clumps in Parkinson’s Disease Skin Samples

By LabMedica International staff writers
Posted on 02 Nov 2020
Print article
Image: A structural model of human alpha-synuclein protein (Photo courtesy of Wikimedia Commons)
Image: A structural model of human alpha-synuclein protein (Photo courtesy of Wikimedia Commons)
A sensitive detection method usually used to identify aggregated prion proteins has been adapted for the diagnosis of Parkinson's disease in skin samples.

An unmet clinical need in Parkinson's disease (PD) has been the identification of biomarkers for diagnosis, preferably in easily accessible tissues such as skin. In this regard previous immunohistochemical studies have detected pathological clumping of alpha‐synuclein (aSyn) protein in skin biopsies from PD patients.

To identify aSyn aggregates in skin samples, investigators at Iowa State University (Ames, USA) used a real‐time quaking‐induced conversion assay. Real-time quaking-induced conversion (RT-QuIC) is a highly sensitive assay generally used for prion detection. The "quaking" in the name of the technique refers to the fact that samples in the RT-QuIC assay are literally subjected to shaking. This action breaks apart aggregates of prion protein (PrP) that are then further incubated, amplifying the amount of misfolded PrP to detectable levels.

The investigators adapted the RT-QuIC assay to determine the seeding kinetics of the aSyn present in the skin from autopsied subjects consisting of frozen skin tissues from 25 PD and 25 controls and formalin‐fixed paraffin‐embedded skin sections from 12 PD and 12 controls.

Results of the analysis revealed that the assay had correctly identified 24/25 PD and 24/25 controls using frozen skin tissues (96% sensitivity and 96% specificity) compared to 9/12 PD and 10/12 controls using formalin‐fixed paraffin‐embedded skin sections (75% sensitivity and 83% specificity). These results clearly demonstrated the feasibility of using skin tissues for clinical diagnosis of PD by detecting pathological aSyn.

"Since there is no easy and reliable test available for the early diagnosis of Parkinson's disease at present, we think there will be a lot interest in the potential use of skin samples for diagnosis," said senior author Dr. Anumantha Kanthasamy, professor of biomedical sciences at Iowa State University. "Testing skin samples could lead to earlier detection of Parkinson's disease. Earlier diagnosis could allow physicians to test therapeutic strategies designed to slow or prevent the development of advanced symptoms."

The skin test paper was published in the September 22, 2020, online edition of the journal Movement Disorders.

Related Links:
Iowa State University

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Mumps Virus Test
ReQuest Mumps IgG

Print article

Channels

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.